UM  > 健康科學學院
Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials
Zheng W.5; Wang S.7; Ungvari G.S.6; Ng C.H.3; Yang X.-H.5; Gu Y.-H.1; Li M.5; Xiang Y.-Q.2; Xiang Y.-T.7
2017
Source PublicationJournal of Clinical Psychopharmacology
ISSN1533712X 02710749
Volume37Issue:3Pages:341-346
Abstract

Purpose: Weight gain associated with antipsychotics in schizophrenia has been an ongoing concern. This meta-analysis examined the efficacy and safety of amantadine as an adjunctive treatment of weight gain in schizophrenia by systematically searching and analyzing randomized controlled trials (RCTs). RCTs comparing adjunctive amantadinewith placebo in adult patients with schizophrenia were included in the meta-analysis. Methods: Two independent investigators searched the literature and extracted data.Weighted and standardized mean differences (WMDs/SMDs) and risk ratio ± 95% confidence intervals were calculated. Results: Five RCTs (n = 265) with double-blinded design lasting 8.2 ± 5.9 weeks were included in the analysis. Amantadine outperformed placebo regarding weight reduction with moderate effect size (trials, 3; n = 205; WMD -2.22 kg; P = 0.001, I2 = 45%). Amantadine also outperformed placebo at endpoint in the negative symptom (the Positive and Negative Syndrome Scale [PANSS] [1 trial] and the Scale for the Assessment of Negative Symptoms [1 trial]) scores (trials, 2; n = 84; SMD, -0.56; P = 0.01, I2 = 12%), but not in the PANSS total scores (trials, 2) (SMD, -0.31; P = 0.16, I2 = 0%) and the positive symptom (PANSS [1 trial] and the Scale for the Assessment of Positive Symptoms [1 trial]) scores (SMD, 0.13; P = 0.54, I2 = 0%). Except for insomnia (P = 0.007; number needed to harm, 6; 95% confidence interval, 4-16), all-cause discontinuation (risk ratio, 1.12; P = 0.54, I2 = 0%) and other adverse events were similar between the amantadine and placebo groups. Conclusions: According to this meta-analysis of 5 RCTs, adjunctive amantadine seems to be an effective option for attenuating antipsychoticrelated weight gain in patients with schizophrenia. More RCTs are needed to inform clinical recommendations.

KeywordAmantadine Meta-analysis Schizophrenia Weight Gain
DOI10.1097/JCP.0000000000000598
URLView the original
Indexed BySCI
WOS Research AreaPharmacology & Pharmacy ; Psychiatry
WOS SubjectPharmacology & Pharmacy ; Psychiatry
WOS IDWOS:000399563300010
Fulltext Access
Citation statistics
Cited Times [WOS]:6   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Beijing Traditional Chinese Medicine Hospital
2.Beijing An Ding Hospital, Capital Medical University
3.University of Melbourne
4.University of Western Australia
5.Guangzhou Medical University
6.University of Notre Dame Australia
7.Universidade de Macau
Recommended Citation
GB/T 7714
Zheng W.,Wang S.,Ungvari G.S.,et al. Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials[J]. Journal of Clinical Psychopharmacology,2017,37(3):341-346.
APA Zheng W..,Wang S..,Ungvari G.S..,Ng C.H..,Yang X.-H..,...&Xiang Y.-T..(2017).Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials.Journal of Clinical Psychopharmacology,37(3),341-346.
MLA Zheng W.,et al."Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials".Journal of Clinical Psychopharmacology 37.3(2017):341-346.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zheng W.]'s Articles
[Wang S.]'s Articles
[Ungvari G.S.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zheng W.]'s Articles
[Wang S.]'s Articles
[Ungvari G.S.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zheng W.]'s Articles
[Wang S.]'s Articles
[Ungvari G.S.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.